VCP
TEVA icon

Verus Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Verus Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$3K Hold
382
– – ﹤0.01% 1302
2019
Q4 		$4K Buy
+382
New +$3.41K ﹤0.01% 1349

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Verus Capital Partners's TEVA Position: Q1 2020 in Review

Verus Capital Partners held its Teva Pharmaceuticals (TEVA) position steady in Q1 2020 at 382 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #1302.

Verus Capital Partners first reported a position in TEVA in Q4 2019 and has held it in 2 quarters since. The position peaked at $4K in Q4 2019. 459 funds tracked by Wall St. Rank hold TEVA as of Q1 2020.

  • Verus Capital Partners held 382 shares of Teva Pharmaceuticals worth $3K as of Q1 2020.
  • Verus Capital Partners left its Teva Pharmaceuticals share count unchanged in Q1 2020.
  • Teva Pharmaceuticals made up ﹤0.01% of Verus Capital Partners's portfolio in Q1 2020, its #1302 holding.
  • Verus Capital Partners first reported a position in Teva Pharmaceuticals in Q4 2019 and has held it in 2 quarters since.
  • Verus Capital Partners's Teva Pharmaceuticals position peaked at $4K in Q4 2019.
  • 459 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.